MarketPulse

HIV treatment

2 articles
BenzingaBenzinga··Vandana Singh

Merck Tumbles 4% as Cancer Trial Fails, Though HIV Approval Offers Lifeline

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.
MRKEXELFDA approvalclinical trial failure
GlobeNewswire Inc.GlobeNewswire Inc.··Actg

Long-Acting HIV Injectable Therapy Outperforms Daily Pills in Phase 3 Trial

Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.
JNJclinical triallong-acting injectable